Instil Bio, Inc. (TIL)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on available-for-sale securities, net | -40 | |||
| Foreign currency translation | -314 | |||
| Other rental income | 2,242 | |||
| Restructuring and impairment charges | 540 | |||
| Research and development | 6,743 | |||
| General and administrative | 6,157 | |||
| In-process research and development | 10,000 | |||
| Total operating expenses | 23,440 | |||
| Loss from operations | -23,440 | |||
| Other income (expense), net | 342 | |||
| Interest income | 1,044 | |||
| Interest expense | 1,582 | |||
| Net loss | -21,394 | |||
| Net comprehensive loss | -21,748 | |||
| Net loss per share, basic (in dollars per share) | -3.24 | |||
| Net loss per share, diluted (in dollars per share) | -3.24 | |||
| Weighted-average shares used in computing net loss per share, basic (in shares) | 6,596,975 | |||
| Weighted-average shares used in computing net loss per share, diluted (in shares) | 6,596,975 | |||